Ivan Pasic

List of Publications by Year
in descending order

26	326	1163117 8	888059 17
papers	citations	h-index	g-index

26	26	26	585
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma. Cancer Research, 2010, 70, 160-171.	0.9	152
2	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 60-69.	2.4	26
3	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. European Journal of Haematology, 2021, 106, 32-39.	2.2	16
4	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2020, 99, 1377-1387.	1.8	15
5	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia and Lymphoma, 2021, 62, 3373-3383.	1.3	12
6	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 428.e1-428.e9.	1.2	11
7	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. Transplantation and Cellular Therapy, 2022, 28, 50.e1-50.e8.	1.2	11
8	Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. Molecular Carcinogenesis, 2018, 57, 106-113.	2.7	10
9	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	2.4	10
10	Antiâ€thymocyte globulin and postâ€transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. European Journal of Haematology, 2022, 108, 61-72.	2.2	9
11	Influence of FLT3â€ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. European Journal of Haematology, 2019, 102, 368-374.	2.2	6
12	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1511-1519.	2.0	6
13	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy, 2022, 28, 265.e1-265.e9.	1.2	6
14	Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. Bone Marrow Transplantation, 2022, 57, 1411-1420.	2.4	6
15	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. Leukemia and Lymphoma, 2021, 62, 2193-2201.	1.3	5
16	Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant. Blood, 2020, 136, 16-17.	1.4	5
17	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 302-310.	0.9	4
18	Antiâ€thymocyte Globulin and Postâ€Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigenâ€A and â€B mismatched donors. European Journal of Haematology, 2022, 108, 288-297.	2.2	4

#	Article	IF	Citations
19	Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164.	2.2	2
20	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2021, 100, 1311-1319.	1.8	2
21	Allogeneic hematopoietic stem cell transplantation in patients with therapyâ€related hematologic malignancies developing after multiple myeloma. European Journal of Haematology, 2022, 108, 430-436.	2.2	2
22	Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal, 2022, 15, 1583-1592.	2.9	2
23	The 17â€gene stemness score associates with relapse risk and longâ€term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem, 2022, 3, 873-884.	1.0	2
24	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. European Journal of Haematology, 2021, 107, 354-363.	2.2	1
25	Refined hepatic grading system in chronic graftâ€versusâ€host disease improves prognostic risk stratification of longâ€term outcomes. European Journal of Haematology, 2021, 106, 508-519.	2.2	1
26	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	0